Significant clinical worsening after natalizumab withdrawal: Predictive factors

Reduction of the washout time between natalizumab and fingolimod

(2013) Jérôme de Seze et al.   Multiple Sclerosis Journal

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate

(2011) Joachim Havla et al.   JOURNAL OF NEUROLOGY

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

(2011) A. Kerbrat et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Natalizumab dosage suspension: Are we helping or hurting?

(2010) Timothy W. West et al.   ANNALS OF NEUROLOGY

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

(2010) Augusto Miravalle et al.   ARCHIVES OF NEUROLOGY

Natalizumab: Bound to rebound?

(2009) N. Schiess et al.   NEUROLOGY